Search This Blog

Friday, January 4, 2019

Tetraphase initiated at B. Riley FBR


Tetraphase resumed with a Buy at B. Riley FBR. B. Riley FBR analyst David Buck resumed coverage of Tetraphase Pharmaceuticals with a Buy rating and $3 price target.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)